Construction has begun on the $91 million vaccine manufacturing facility that GlaxoSmithKline ($GSK) is building in partnership with the U.S. government and Texas A&M University and should be completed by the end of next year. Officials last week dedicated the facility, which will make influenza vaccine and can be called on to produce bulk antigen to help the U.S. produce up to 50 million doses of vaccine within four months in the event of a pandemic. Startup and validation of the 100,000-square-foot facility is expected to be complete by early 2017. A viral-based vaccine facility is also being designed and will be built adjacent to the influenza vaccine facility. Release | More